MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 893 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK3-IN-13
JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.Formula:C25H33ClN6O5Color and Shape:SolidMolecular weight:533.02pan-KRAS degrader 1
CAS:Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.Formula:C22H26N8OSColor and Shape:SolidMolecular weight:450.56J-104871
CAS:J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.Formula:C38H32N2O12Purity:98%Color and Shape:SolidMolecular weight:708.67KRAS G12D inhibitor 16
CAS:KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.Formula:C32H39IN6O3Color and Shape:SolidMolecular weight:682.59ERK-IN-2
CAS:ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].Formula:C16H18ClN5O2Purity:98%Color and Shape:SolidMolecular weight:347.80Brimarafenib
CAS:Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit BRAF and CRAF, and exhibits inhibitory effects on a variety of RAF mutations.Formula:C24H17F3N4O4Purity:98.32%Color and Shape:SolidMolecular weight:482.41MRTX849 acid
CAS:MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.Formula:C34H37ClFN7O4Color and Shape:SolidMolecular weight:662.16KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Formula:C22H17ClF2N6OSColor and Shape:SolidMolecular weight:486.93KRAS G12C inhibitor 33
CAS:KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63KRAS ligand 5
CAS:KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.Formula:C30H30F2N4O4Color and Shape:SolidMolecular weight:548.58MNK1 ligand 1
CAS:MNK1ligand 1 (Compound 5) is an MNK1 ligand used in the synthesis of PROTACMNK1 degrader-1.Formula:C15H17N3OSColor and Shape:SolidMolecular weight:287.38MK2-IN-4
CAS:MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.Formula:C25H24N4O2Color and Shape:SolidMolecular weight:412.48HPK1-IN-14
CAS:HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.Formula:C24H23FN6O2Color and Shape:SolidMolecular weight:446.48AM-001
CAS:AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.Formula:C24H16FN3OS2Color and Shape:SolidMolecular weight:445.53KRAS inhibitor-36
CAS:KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.Formula:C14H13NO4Color and Shape:SolidMolecular weight:259.26AZD4625
AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.Formula:C24H21ClF2N4O3Color and Shape:SolidMolecular weight:486.9ABS-752
CAS:ABS-752 is an effective and orally active molecular glue degrader targeting GSPT1 and NEK7. It exhibits cytotoxic properties and reduces the protein expression of GSPT1, SALL4, and NEK7. ABS-752 possesses anticancer activity and shows potential for research in hepatocellular carcinoma.Formula:C14H14FN3O3Color and Shape:SolidMolecular weight:291.28SOS1-IN-10
SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).Formula:C22H19F5N4OColor and Shape:SolidMolecular weight:450.4pan-KRAS-IN-17
CAS:pan-KRAS-IN-17 (Example 34) is an inhibitor that targets multiple forms of the KRAS protein.Formula:C34H33F3N5O8PColor and Shape:SolidMolecular weight:727.623KRAS G12C inhibitor 46
CAS:KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.Formula:C32H33F2N7O2Color and Shape:SolidMolecular weight:585.65KRAS inhibitor-35
CAS:KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.Formula:C38H32F4N6O3SColor and Shape:SolidMolecular weight:728.76KRAS inhibitor-21
CAS:KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.Formula:C33H41N5O3Color and Shape:SolidMolecular weight:555.71Everafenib
Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.Formula:C20H23ClFN5O2S2Color and Shape:SolidMolecular weight:484.01G12Si-1
G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.Formula:C29H32ClN5O3Color and Shape:SolidMolecular weight:534.05MAP855
CAS:MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.Formula:C28H23ClF2N6O3Color and Shape:SolidMolecular weight:564.97ZCL279
CAS:ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.Formula:C24H18N2O7S2Color and Shape:SolidMolecular weight:510.539Dioleyl phosphatidylserine
CAS:Dioleyl phosphatidylserine is a phospholipid that can activate PKC-γ (Protein Kinase C-gamma) when the Ca2+ concentration is below 0.5 μM, specifically at a concentration of 100 μM.Formula:C42H78NO10PColor and Shape:SolidMolecular weight:788.04KRas G12C inhibitor 2
CAS:KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.Formula:C32H37N7O3Purity:98%Color and Shape:SolidMolecular weight:567.68Luvometinib
CAS:Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.Formula:C26H22F2IN5O4SColor and Shape:SolidMolecular weight:665.45Nek2/Hec1-IN-3
CAS:Nek2/Hec1-IN-3 (Compound 11-28) is an inhibitor of the Hec1/Nek2 interaction. It disrupts the binding between Nek2 and Hec1 and is applicable for research in tumor diseases.Formula:C16H13N3OSColor and Shape:SolidMolecular weight:295.36PS-166276
CAS:PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.Formula:C20H30N8OColor and Shape:SolidMolecular weight:398.51KRAS G12D inhibitor 28
CAS:KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.Formula:C35H32Cl2FN5OColor and Shape:SolidMolecular weight:628.57PF-03715455
CAS:PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.Formula:C35H34ClN7O3S2Purity:98%Color and Shape:SolidMolecular weight:700.27OZO-H
CAS:OZO-H is a GST inhibitor and a potent anticancer derivative of OZO. It releases JNK1 from the GST-JNK1 complex, induces JNK1 phosphorylation, and activates c-Jun in cancer cells.Formula:C8H5NO2SColor and Shape:SolidMolecular weight:179.20MLKL-IN-1
MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.Formula:C19H20N2O3Color and Shape:SolidMolecular weight:324.37INCB159020
CAS:INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.Formula:C37H35ClFN7O2Color and Shape:SolidMolecular weight:664.171GDC-6036-NH
CAS:GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.Formula:C26H30ClF4N7OPurity:99.84%Color and Shape:SolidMolecular weight:568.01KRAS inhibitor-13
CAS:KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.Formula:C25H19ClFN3O2SColor and Shape:SolidMolecular weight:479.95KRAS G12D inhibitor 1
CAS:KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].Formula:C33H32F2N6O2Color and Shape:SolidMolecular weight:582.64p38-α MAPK-IN-5
CAS:p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.Formula:C37H49N11O2Color and Shape:SolidMolecular weight:679.86Casein kinase 1δ-IN-31
CAS:Casein kinase1δ-IN-31 (Compound 16) is an inhibitor of casein kinase (CK), specifically targeting CK1α, CK1δ, and p38α, with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, Casein kinase1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM.Formula:C17H13FN4Color and Shape:SolidMolecular weight:292.31p38-α MAPK-IN-9
CAS:p38-α MAPK-IN-9 (Compound 25a) is a p38-α MAPK inhibitor with a Ki value of 0.057 nM. It effectively inhibits LPS-induced TNFα production in hPBMC cells, exhibiting an IC50 of 18 nM.Formula:C19H20N8O2Color and Shape:SolidMolecular weight:392.414ADT-1004
CAS:ADT-1004 is an inhibitor of RAS. It can be used for research involving Ras-mediated diseases.Formula:C33H36FN3O6Color and Shape:SoildMolecular weight:589.65p38-α MAPK-IN-10
CAS:p38-α MAPK-IN-10 (Compound 6) is an inhibitor of p38α, with an IC50 value of 4 nM.Formula:C27H34Cl2N6Color and Shape:SolidMolecular weight:513.505CK1δ-IN-9
CAS:CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.Formula:C16H12FN5Color and Shape:SolidMolecular weight:293.298KRAS G12C inhibitor 15
CAS:KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .Formula:C25H21ClF2N4O3Purity:98%Color and Shape:SolidMolecular weight:498.91AMG-548 hydrochloride
AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.Formula:C29H28ClN5OColor and Shape:SolidMolecular weight:498.02JNK-IN-21
CAS:JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.Formula:C19H16N2O2SColor and Shape:SolidMolecular weight:336.408FMK-MEA
CAS:FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.Formula:C21H26FN5O2Purity:98%Color and Shape:SolidMolecular weight:399.46SHR902275
CAS:SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.Formula:C26H23F3N4O4Color and Shape:SolidMolecular weight:512.48
